Sandu Pharmaceuticals Intrinsic Value
SANDUPHQ Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹29.92 | ₹23.94 - ₹35.90 | -16.0% | EPS: ₹1.36, Sector P/E: 22x |
| Book Value Method | asset | ₹84.00 | ₹75.60 - ₹92.40 | +136.0% | Book Value/Share: ₹42.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹71.20 | ₹64.08 - ₹78.32 | +100.0% | Revenue/Share: ₹56.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹38.30 | ₹34.47 - ₹42.13 | +7.6% | EBITDA: ₹4.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹14.24 | ₹11.39 - ₹17.09 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹10.68 | ₹9.61 - ₹11.75 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹21.01 | ₹18.91 - ₹23.11 | -41.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹35.85 | ₹32.27 - ₹39.44 | +0.7% | EPS: ₹1.36, BVPS: ₹42.00 |
| Dividend Yield Method | dividend | ₹32.00 | ₹28.80 - ₹35.20 | -10.1% | DPS: ₹0.80, Target Yield: 2.5% |
Want to compare with current market value? Check SANDUPHQ share price latest .
Valuation Comparison Chart
SANDUPHQ Intrinsic Value Analysis
What is the intrinsic value of SANDUPHQ?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Sandu Pharmaceuticals (SANDUPHQ) is ₹32.00 (median value). With the current market price of ₹35.60, this represents a -10.1% variance from our estimated fair value.
The valuation range spans from ₹10.68 to ₹84.00, indicating ₹10.68 - ₹84.00.
Is SANDUPHQ undervalued or overvalued?
Based on our multi-method analysis, Sandu Pharmaceuticals (SANDUPHQ) appears to be trading above median value by approximately 10.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.33 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Operating Margin | 3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.00x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Sandu Pharmaceuticals
Additional stock information and data for SANDUPHQ
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |